$4888 | SAVE $862 | Single User
$9775 | SAVE $1,725 | Site License
$14663 | SAVE $2,587 | Enterprise License

Nonalcoholic Steatohepatitis - Market Insights, Epidemiology and Market Forecast – 2027

Nonalcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology and Market Forecast – 2027
[Lowest Price Guaranteed: $4,888]

Published by Delve Insight: 01 Sep 2017 | 118079 | In Stock
Related Topics: Steatohepatitis

Introduction

DelveInsight’s ‘Nonalcoholic Steatohepatitis (NASH)- Market Insights, Epidemiology and Market Forecast-2027’ report provides a disease overview of the Nonalcoholic Steatohepatitis (NASH) along with the epidemiology and the market scenario in the 7MM – United States, EU5 (Germany, France, Spain Italy , United Kingdom) and Japan.

The Report covers the therapeutics market revenue, treatment practice and Nonalcoholic Steatohepatitis (NASH) forecasted market share from 2017 to 2027 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Nonalcoholic Steatohepatitis (NASH) till 2027. Our epidemiology forecast covers the prevalent population as well as the diagnosed population having Nonalcoholic Steatohepatitis (NASH).

The report also covers the detailed market size forecast for 7MM. According to DelveInsight, it is estimated that the market size of Nonalcoholic Steatohepatitis (NASH) in 7MM shall increase and reach up to 49.25 Billion in 2027, with the compound annual growth rate (CAGR) of 23.0% for the period i.e., 2015-2027.

Nonalcoholic Steatohepatitis (NASH) is a subtype of NAFLD (Nonalcoholic Fatty Liver Disease) that is characterized by accumulation of large amount of fat in the liver, along with inflammation and scarring. NASH is one of the most common liver related health problem and is considered to be strongly associated with insulin resistance, central obesity, reduced glucose tolerance, type 2 diabetes mellitus (T2DM), arterial hypertension, and hypertriglyceridemia. The condition can further progress to cirrhosis, liver failure and rarely liver cancer.

Key Coverage and Benefits:

• The report will help in developing business strategies by understanding the trends shaping and driving the global Nonalcoholic Steatohepatitis (NASH) market.

• Organize sales and marketing efforts by identifying the best opportunities for Nonalcoholic Steatohepatitis (NASH) in US, European Union 5 (EU5- Germany, Spain, Italy, France and United Kingdom) and Japan.

• To understand the future market competition in the global Nonalcoholic Steatohepatitis (NASH) market and Insightful review of the key market drivers and barriers.

• To understand the regulatory scenario in major markets.

Table of Contents
for Nonalcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology and Market Forecast – 2027

  • 1. Report Introduction

    2. Non-Alcoholic Steatohepatitis Market Overview at a Glance

    3. Total Market Share Distribution of Non-Alcoholic Steatohepatitis for 7 MM in 2016

    4. Total Market Share Distribution of Non-Alcoholic Steatohepatitis for 7 MM in 2027

    5. Non-Alcoholic Steatohepatitis

    5.1. Introduction

    5.2. Types

    5.3. Classification of NASH: Stages of Fibrosis

    5.4. Causes

    5.5. Pathophysiology

    5.6. Symptoms

    5.7. Diagnosis

    6. Epidemiology and Patient Population

    7. Key Points:

    8. Population and Forecast Parameters

    9. Prevalent Population of NASH in 7MM

    10. Region-Wise Prevalent Population of NASH

    11. Diagnosed Population of NASH in 7MM

    12. Region-Wise Diagnosed Population of NASH

    12.1. United States

    12.1.1. Prevalent Population of NASH

    12.1.2. Diagnosed Population of NASH

    12.2. Germany

    12.2.1. Prevalent Population of NASH

    12.2.2. Diagnosed Population of NASH

    12.3. France

    12.3.1. Prevalent Population of NASH

    12.3.2. Diagnosed Population of NASH

    12.4. Italy

    12.4.1. Prevalent Population of NASH

    12.4.2. Diagnosed Population of NASH

    12.5. Spain

    12.5.1. Prevalent Population of NASH

    12.5.2. Diagnosed Population of NASH

    12.6. United Kingdom

    12.6.1. Prevalent Population of NASH

    12.6.2. Diagnosed Population of NASH

    12.7. Japan

    12.7.1. Prevalent Population of NASH

    12.7.2. Diagnosed Population of NASH

    13. Treatment Algorithm

    14. American Association for the Study of Liver Diseases (AASLD) Current Recommendations for NAFLD/NASH

    15. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

    16. Guideline for NAFLD/NASH, by the Japanese Society of Gastroenterology (JSG) in cooperation with “The Japan Society of Hepatology”

    17. Unmet Needs

    18. Emerging Drugs

    18.1. Phase-III Drugs Analysis

    18.2. Phase-II Drugs Analysis

    19. Emerging Therapies

    19.1. Elafibranor(GFT505): GenfitPharma

    19.1.1. Regulatory Milestones

    19.1.2. Other development activities

    19.1.3. Clinical Development

    19.1.4. Ongoing Trials Information

    19.1.5. Safety and Efficacy

    19.1.6. Advantages and Disadvantages

    19.1.7. Product Profile

    19.2. Obeticholic Acid (OCA): Intercept Pharmaceuticals, Inc.

    19.2.1. Regulatory milestones

    19.2.2. Other development activities

    19.2.3. Clinical Development

    19.2.4. Ongoing Trials Information

    19.2.5. Safety and Efficacy

    19.2.6. Advantages and Disadvantages

    19.2.7. Product Profile

    19.3. Selonsertib (Ask-1 Inhibitor): Gilead Sciences, Inc.

    19.3.1. Other development activities

    19.3.2. Clinical Development

    19.3.3. Clinical Pipeline Activity

    19.3.4. Safety and Efficacy

    19.3.5. Advantages and Disadvantages

    19.3.6. Product Profile

    19.4. Cenicriviroc (CVC): Allergan/Tobira Therapeutics

    19.4.1. Regulatory milestones

    19.4.2. Other development activities

    19.4.3. Clinical Development

    19.4.4. Ongoing Trials Information

    19.4.5. Safety and Efficacy

    19.4.6. Advantages and Disadvantages

    19.4.7. Product Profile

    19.5. NGM282: NGM Biopharmacueticals, Inc.

    19.5.1. Other development activities

    19.5.2. Clinical Development

    19.5.3. Ongoing Trials Information

    19.5.4. Safety and Efficacy

    19.5.5. Advantages and Disadvantages

    19.5.6. Product Profile

    19.6. BMS-986036:Bristol-Myers Squibb Company

    19.6.1. Other development activities

    19.6.2. Clinical Development

    19.6.3. Ongoing trials information

    19.6.4. Safety and Efficacy

    19.6.5. Advantages and Disadvantages

    19.6.6. Product Profile

    19.7. Emricasan: Conatus Pharmaceuticals Inc.

    19.7.1. Regulatory milestones

    19.7.2. Other development activities

    19.7.3. Clinical Development

    19.7.4. Ongoing trials information

    19.7.5. Safety and Efficacy

    19.7.6. Product Profile

    19.8. IVA337: Inventiva Pharma

    19.8.1. Regulatory milestones

    19.8.2. Clinical Development

    19.8.3. Ongoing trial information

    19.8.4. Safety and Efficacy

    19.8.5. Product Profile

    20. Nonalcoholic Steatohepatitis (NASH): Country-Wise Market Analysis

    20.1. Total Market Size of Nonalcoholic Steatohepatitis (NASH) for 7 MM in 2015-2027

    21. United States

    21.1. Market Size of NASH in United States

    22. Europe

    23. Germany

    23.1. Market Size of NASH in Germany

    24. France

    24.1. Market Size of NASH in France

    25. Italy

    25.1. Market Size of NASH in Italy

    26. Spain

    26.1. Market Size of NASH in Spain

    27. United Kingdom

    27.1. Market Size of NASH in United Kingdom

    28. Japan

    28.1. Market Size of NASH in Japan

    29. Market Drivers

    30. Market Barriers

    31. Appendix

    32. Report Methodology

    33. Consulting Services

    34. Disclaimer

    35. About DelveInsight

List Of Tables
in Nonalcoholic Steatohepatitis - Market Insights, Epidemiology and Market Forecast – 2027

Table 1: Total Prevalent Population of NASH in 7 MM (2015-2027)

Table 2: Region-Wise Prevalent Population of NASH (2015-2027)

Table 3: Total Diagnosed Population of NASH in 7 MM (2015-2027)

Table 4: Region-Wise Diagnosed Population of NASH (2015-2027)

Table 5: Prevalent Population of NASH based on Fibrosis Score in United States (2015-2027)

Table 6: Diagnosed Population of NASH in United States (2015-2027)

Table 7: Prevalent Population of NASH based on Fibrosis Score in Germany (2015-2027)

Table 8: Diagnosed Population of NASH in Germany (2015-2027)

Table 9: Prevalent Population of NASH based on Fibrosis Score in France (2015-2027)

Table 10: Diagnosed Population of NASH in France (2015-2027)

Table 11: Prevalent Population of NASH based on Fibrosis Score in Italy (2015-2027)

Table 12: Diagnosed Population of NASH in Italy (2015-2027)

Table 13: Prevalent Population of NASH based on Fibrosis Score in Spain (2015-2027)

Table 14: Diagnosed Population of NASH in Spain (2015-2027)

Table 15: Prevalent Population of NASH based on Fibrosis Score in United Kingdom (2015-2027)

Table 16: Diagnosed Population of NASH in United Kingdom (2015-2027)

Table 17: Prevalent Population of NASH based on Fibrosis Score in Japan (2015-2027)

Table 18: Diagnosed Population of NASH in Japan (2015-2027)

Table19 : Treatment Algorithm of Nonalcoholic Steatohepatitis (NASH)

Table20 : Medications for Nonalcoholic Steatohepatitis (NASH)

Table 21 : Management of NAFLD based on histology

Table 22 : AASLD Current Recommendations for NAFLD/NASH

Table 23 : EASL–EASD–EASO Clinical Practice Guidelines for the management of NAFLD

Table 24 : Guideline for NAFLD/NASH, by the Japanese Society of Gastroenterology (JSG)

Table 25: Market Size of Nonalcoholic Steatohepatitis (NASH) in 7MM (USD Billion) (2015-2027)

Table 26: United States Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)

Table 27: Germany Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)

Table 28: France Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)

Table 29: Italy Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)

Table 30: Spain Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)

Table 31: United Kingdom Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)

Table 32: Japan Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)

List Of Figures, Charts and Diagrams
in Nonalcoholic Steatohepatitis - Market Insights, Epidemiology and Market Forecast – 2027

Figure 1: Types of NASH

Figure 2: Stages of NASH

Figure 3: Classification of NASH

Figure 4: Pathophysiology of NASH

Figure 5: Pathophysiology of NASH: Lipolysis of adipose tissue

Figure 6: Pathophysiology of NASH: Dietary factors

Figure 7: Pathophysiology of NASH: Kupffer cells

Figure 8: Total Prevalent Population of NASH in 7 MM (2015-2027)

Figure 9: Region-Wise Prevalent Population of NASH (2015-2027)

Figure 10: Total Diagnosed Population of NASH in 7 MM (2015-2027)

Figure 11: Region-Wise Diagnosed Population of NASH (2015-2027)

Figure 12: Prevalent Population of NASH based on Fibrosis Score in United States (2015-2027)

Figure 13: Diagnosed Population of NASH in United States (2015-2027)

Figure 14: Prevalent Population of NASH based on Fibrosis Score in Germany (2015-2027)

Figure 15: Diagnosed Population of NASH in Germany (2015-2027)

Figure 16: Prevalent Population of NASH based on Fibrosis Score in France (2015-2027)

Figure 17: Diagnosed Population of NASH in France (2015-2027)

Figure 18: Prevalent Population of NASH based on Fibrosis Score in Italy (2015-2027)

Figure 19: Diagnosed Population of NASH in Italy (2015-2027)

Figure 20: Prevalent Population of NASH based on Fibrosis Score in Spain (2015-2027)

Figure 21: Diagnosed Population of NASH in Spain (2015-2027)

Figure 22: Prevalent Population of NASH based on Fibrosis Score in United Kingdom (2015-2027)

Figure 23: Diagnosed Population of NASH in United Kingdom (2015-2027)

Figure 24: Prevalent Population of NASH based on Fibrosis Score in Japan (2015-2027)

Figure 25: Diagnosed Population of NASH in Japan (2015-2027)

Figure 26: Unmet needs: NASH

Figure 27: United States Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)

Figure 28: Germany Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)

Figure 29: France Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Million (2015-2027)

Figure 30:Italy Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)

Figure 31:Spain Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Billion (2015-2027)

Figure 32: United Kingdom Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Million (2015-2027)

Figure 33:Japan Market Size of Nonalcoholic Steatohepatitis (NASH) in USD, Million (2015-2027)

Figure 34: Market Drivers: NASH

Figure 35:Market Barriers: NASH

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

118079 | DIMI0019

Number of Pages

120

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Nonalcoholic Steatohepatitis Therapeutics in Asia-Pacific Markets to 2024 - Launch of NASH-Specific Premium Products and Rising Prevalence to Drive the Market
Nonalcoholic Steatohepatitis Therapeutics in Asia-Pacific Markets to 2024 - Launch of NASH-Specific ...
03 Dec 2018 by GBI Research USD $4,246 (normally
USD $4,995)
More Info
SAVE 15% today! Nonalcoholic Steatohepatitis (NASH) - Epidemiology Forecast To 2023
DelveInsight “Nonalcoholic Steatohepatitis (NASH) - Epidemiology Forecast To 2023” provides an overv...
31 May 2017 by Delve Insight USD $2,338 (normally
USD $2,751)
More Info
SAVE 15% today! Nonalcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology and Market Forecast-2023
Note*: This report requires 5-7 business days to complete.DelveInsight’s Nonalcoholic Steatohepatiti...
30 May 2017 by Delve Insight USD $4,208 (normally
USD $4,951)
More Info
SAVE 15% today! Global Nonalcoholic Fatty Liver Disease Market Research Report Forecast 2017 to 2021
The Global Nonalcoholic Fatty Liver Disease Market Research Report Forecast 2017-2021 is a valuable ...
15 May 2017 by S&P Consulting USD $2,380 (normally
USD $2,800)
More Info
SAVE 15% today! Nonalcoholic Drinks Market by Product Type (Soft Drinks, Bottled Water, Tea & Coffee, Juice, Dairy Drinks, and Others) - Global Opportunity Analysis and Industry Forecast, 2014-2022
Nonalcoholic drinks, also known as ‘virgin drinks’, ‘mocktails’ and ‘n...
20 Dec 2016 by Allied Market Research USD $4,565 (normally
USD $5,371)
More Info
SAVE 15% today! Nonalcoholic Drinks Market by Product Type (Soft Drinks, Bottled Water, Tea & Coffee, Juice, Dairy Drinks, and Others) - Global Opportunity Analysis and Industry Forecast, 2014-2022
Nonalcoholic drinks, also known as ‘virgin drinks’, ‘mocktails’ and ‘near beer’, refer to the bevera...
01 Dec 2016 by Allied Market Research USD $4,029 (normally
USD $4,740)
More Info
SAVE 15% today! Nonalcoholic Drinks Market by Product Type (Soft Drinks, Bottled Water, Tea & Coffee, Juice, Dairy Drinks, and Others) - Global Opportunity Analysis and Industry Forecast, 2014-2022
Nonalcoholic drinks, also known as ‘virgin drinks’, ‘mocktails’ and ‘near beer’, refer to the bevera...
01 Dec 2016 by Allied Market Research USD $4,565 (normally
USD $5,371)
More Info
SAVE 15% today! Nonalcoholic Steatohepatitis (NASH): KOL Insight
IntroductionWho will benefit most from huge opportunities in NASH treatment?The first new NASH thera...
01 May 2016 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info
SAVE 15% today! Nonalcoholic Steatohepatitis (NASH): KOL Insight
Who will benefit most from huge opportunities in NASH treatment?The first new NASH therapy is due so...
01 May 2016 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info
SAVE 15% today! Nonalcoholic Steatohepatitis: KOL Insight
IntroductionWhy This Report is Essential Expect a revolution in the treatment of nonalcoholic steato...
01 Mar 2015 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Download Free Report Summary PDF

Nonalcoholic Steatohepatitis (NASH) - Market Insights, Epidemiology and Market Forecast – 2027 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...